Advanced primary nonurachal adenocarcinoma of urinary bladder responding to modified FOLFOX6 and capecitabine: a case report | Zendy

Frank S. Fan | Zendy; Chung-Fan Yang | Zendy

Open Access

Advanced primary nonurachal adenocarcinoma of urinary bladder responding to modified FOLFOX6 and capecitabine: a case report

Author(s) -

Frank S. Fan,

Chung-Fan Yang

Publication year - 2018

Publication title -

oxford medical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.169

H-Index - 9

ISSN - 2053-8855

DOI - 10.1093/omcr/omy050

Subject(s) - medicine , oxaliplatin , capecitabine , urinary bladder , regimen , adenocarcinoma , oncology , colorectal cancer , chemotherapy , urinary system , urology , cancer

Careful morphology and immunohistochemistry study can make an accurate differential diagnosis of primary adenocarcinoma of urinary bladder from metastatic lesions involving bladder, especially cancer arising in colon, but there is yet no consensus regarding the standard chemotherapy for advanced adenocarcinoma of urinary bladder among medical oncologists. Sustained response to modified FOLFOX6 (fluorouracil, oxaliplatin plus leucovorin) regimen and oral capecitabine for multiple metastases in a patient with primary nonurachal adenocarcinoma of urinary bladder is presented here as a strong support that the frontline chemotherapy for this infrequent malignant disease is just like what could be chosen for colorectal cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research